Evidence map›Paper›PMID 41291135›Full record

ArticleFunctional & integrative genomics2025

Systematic evaluation of CrRNA design parameters for optimized Cas13d-mediated RNA targeting in chicken cells.

Emily Hann, Debolina Majumdar, Daniel Layton, Mohamed Fareh, David M Cahill, Mark Ziemann, Beata Ujvari, Karel A Schat, Arjun Challagulla

Abstract read
In one paragraph

Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emily HannAustralian Centre for Disease Preparedness, CSIRO Health and Biosecurity, Geelong, VIC, Australia.
Debolina MajumdarAustralian Centre for Disease Preparedness, CSIRO Health and Biosecurity, Geelong, VIC, Australia.
Daniel LaytonAustralian Centre for Disease Preparedness, CSIRO Health and Biosecurity, Geelong, VIC, Australia.
Mohamed FarehPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
David M CahillSchool of Life and Environmental Sciences, Deakin University, Geelong, VIC, Australia.
Mark ZiemannBurnet Institute, Melbourne, VIC, Australia.
Beata UjvariSchool of Life and Environmental Sciences, Deakin University, Geelong, VIC, Australia.
Karel A SchatDepartment of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Arjun ChallagullaAustralian Centre for Disease Preparedness, CSIRO Health and Biosecurity, Geelong, VIC, Australia. Arjun.Challagulla@csiro.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CRISPR-Cas13 system has emerged as a powerful platform for programmable RNA targeting, offering efficient and sequence-specific silencing of coding and non-coding transcripts. The RNA-targeting capabilities of CRISPR-Cas13 have been harnessed to silence transcripts harbouring pathogenic mutations and combat infectious diseases. However, the molecular basis of on-target and collateral activity are not completely understood, limiting the utility of Cas13 systems. In this study, we delineate the principles for the development of effective crRNAs by targeting DsRed fluorescence reporter and synthetic influenza mRNA in chicken fibroblast DF1 cells. To systematically determine the optimal design for RfxCas13d crRNA, we investigated the minimum length of the crRNA, importance of protospacer flanking sequence, degree of mismatch tolerance, and off target effects. Our data reveal variable knockdown levels between crRNAs, in which several crRNAs achieved over 95% target knockdown. We show that crRNAs exhibit a high degree of tolerance to single-nucleotide mismatches, regardless of their position in the spacer sequence. However, 4-nt mismatches between the spacer and the target significantly reduces targeting efficacy, whereas eight nucleotide mismatches completely abolish the activity of RfxCas13d. Finally, we compared targeting efficiency and collateral activity of two widely used RfxCas13d and HfCas13d variants. Our data extend current understanding of Cas13d-mediated RNA targeting and offer a framework for rational crRNA design to enhance effectiveness in diverse applications, including antiviral strategies.

Indexed as

CRISPR-Cas SystemsAnimalsCell LineChickensRNA, MessengerRNA, MessengerChickenCRISPR-Cas13CrRNA designMismatch toleranceRNA-targeting

Identifiers

PMID41291135
PMCPMC12647337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.